Search

Background: This study aimed to compare the shear bond strength (SBS) of ceramic and metal brackets bonded to the enamel using Grengloo color-change adhesive and Transbond XT conventional composite. Materials and Methods: In this in vitro, experimental study, 120 extracted human premolars were divided into four groups: (1) Grengloo with metal brackets, (2) Grengloo with ceramic brackets, (3) Transbond XT with metal brackets, and (4) Transbond XT with ceramic brackets. After bracket bonding, the teeth were subjected to 500 thermal cycles and incubated at 37°C for 24 h. The SBS was measured and the data were analyzed using two-way ANOVA. Mann–Whitney U test was used to compare the Adhesive Remnant Index (ARI) scores. was statistically significant (P < 0.001) Results: The effect of type of bracket (metal/ceramic) on SBS was not statistically significant (P = 0.368). However, the effect of type of composite on SBS was statistically significant (P < 0.001) and the SBS of Grengloo was higher than that of Transbond XT. No significant difference was found in ARI scores among the groups. Conclusion: Regarding the high SBS and the safe region of bond failure in Grengloo composite, this color-change adhesive can be a suitable alternative in cases that require high bond strength. Furthermore, the color contrast of Grengloo can make composite removal easier than Transbond XT with color match of composite and teeth.

Background: Hyperuricemia has been associated with the development of high blood pressure (BP). We studied the effects of allopurinol therapy in hyperuricemic hemodialysis (HD) patients with high BP. Materials and Methods: This single-blind, randomized cross-over clinical study involved 55 HD patients with serum uric acid level > 6.5 (men) and > 5.5 mg/dL (women). They were randomly divided in two groups, each of which went through two phases. Group-1 in phase-1 received 100 mg/day orally of allopurinol for three months; while Group-2 was given whatever medication they received prior to the study. After two months of washing period, the groups were crossed-over. The BP levels were measured before and after HD during the eight months study period. Results: Fifty-three patients completed the study (33 men and 20 women, with mean age of 55.8 years). Uric acid levels decreased significantly during the12 weeks of allopurinol therapy (7.71 ± 1.53 to 5.2 ± 1.2 P < 0.005). Overall, after the 12 weeks of allopurinol therapy, systolic and diastolic BP also significantly decreased in allopurinol group, 15.8% (139 to 117, P < 0.0005) and 8.6% (81 to 74, P < .0005), respectively. There were not significant changes in body mass index, blood urea nitrogen, creatinine, albumin, cholesterol, triglyceride, hemoglobin, liver enzymes and serum electrolytes level after treatment. Patients treated with allopurinol had a significant increase in the quality of dialysis (KT/V) (P: 0.043). Conclusions: In HD patients, allopurinol treatment reduced BP. The results indicate a new potential therapeutic approach for controlling BP in HD patients.